The Biomedical Catalyst programme supports innovation projects addressing key health and healthcare challenges, which aligns with the venture's goal of predicting drug resistance mutations. The programme's focus on industry-led research and development also matches the venture's pre-seed stage and plans for collaboration with pharmaceutical companies. The funding amount and geography are also a good fit, as the venture is seeking non-dilutive funding and targeting the UK market.